Publications by authors named "Yu-He Tang"
Lysosomal storage diseases (LSDs) are genetic disorders caused by mutations in lysosomal enzymes, lysosomal membrane proteins or genes related to intracellular transport that result in impaired lysosomal function. Currently, the primary treatment for several LSDs is enzyme replacement therapy (ERT), which involves intravenous administration of the deficient lysosomal enzymes to ameliorate symptoms. The efficacy of ERT largely depends on the mannose-6-phosphate (M6P) modification of the N-glycans associated with the enzyme, as M6P is a marker for the recognition and trafficking of lysosomal enzymes.
View Article and Find Full Text PDFArticle Synopsis
- * In studies using cells lacking the MOGS gene (encoding an enzyme important for glycan processing) and components of the CANX/CALR cycle, significant changes were observed in protein expression and glycosylation patterns, particularly affecting oligomannosidic -glycans.
- * The research revealed that lysosomal hydrolases in the defective cells were poorly modified and improperly secreted, highlighting the important role of the CANX/CALR cycle in
Article Synopsis
- Cancer antigen 125 (CA125) is a blood marker used to detect ovarian cancer, but its levels can also rise due to non-cancerous conditions, making diagnosis tricky.
- Researchers engineered cells to express CA125 that carries the Tn antigen, hoping to improve the accuracy of ovarian cancer diagnosis.
- They achieved this by knocking out specific genes in kidney cells to increase Tn antigen levels, using a system to anchor CA125 to the cell surface, and ultimately converting it to a form that can be secreted for better detection.